Mission Therapeutics moves kidney disease drug to phase 2 after FDA approval
Outsourcing Pharma
DECEMBER 14, 2023
Mission Therapeutics, a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to proceed with a phase 2 trial for its kidney treatment MTX652.
Let's personalize your content